Background & aim: Glucagon influences kidney function through both direct intrarenal glucagon receptor (GCGR) signaling and indirect humoral pathways. Increasing evidence suggests that renal GCGR activity is impaired in chronic kidney disease (CKD). Survodutide is a novel, long-acting dual GCGR/GLP-1…
Background & aim: Obesity pharmacotherapy has significantly improved weight management, with semaglutide (GLP-1 receptor agonist), tirzepatide (dual GLP-1 and GIP receptor agonist) and survodutide (dual glucagon/GLP-1 receptor agonist) demonstrating substantial efficacy in reducing body weight. These drugs primarily act by…
Abstract: Survodutide is a novel GCG/GLP-1 receptor (GCGR/GLP-1R) dual agonist in clinical development for people with obesity and people with metabolic dysfunction-associated steatohepatitis (MASH). Preclinically, survodutide demonstrated body weight lowering efficacy through decreased energy intake and increased energy expenditure. Here,…
Background & aim: Nutrient-stimulated gut hormone peptide YY3e36 (PYY3e36) selectively activates the neuropeptide Y2 receptor (NPY2R) and reduces energy intake in humans. We describe the discovery and pharmacology of the long-acting NPY2R agonist BI 1820237 and its potential bodyweight-lowering efficacy…
Background & aim: OPK-88006 is a novel peptide-based, long-acting glucagon-like peptide-1 receptor (GLP1R)/glucagon receptor (GCGR) dual agonist in current preclinical development for metabolic diseases, including obesity and metabolic dysfunction-associated steatohepatitis (MASH). The present study aimed to compare the therapeutic profile…
Background & aim: Survodutide is a dual agonist of the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R), currently in clinical development for obesity and related metabolic disorders. By concurrently enhancing GCGR and GLP1R signaling, survodutide offers a synergistic approach…
Scientific Reports 12(1):6666, 2022
Nature Metabolism 2(5):413–431, 2020
Diabetes, Obesity and Metabolism 22(8):1328-1338, 2020
